Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16 December 2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German pharma major Bayer’s (BAYN: DE) Eylea (aflibercept) and Swiss peers Roche (ROG: SIX) and Novartis' (NOVN: VX) Lucentis (ranibizumab) for the treatment of diabetic macular edema (DME), concluding that there was no relevant difference between the two, neither in terms of how well patients could see nor in terms of side effects.

Since August 2014, Eylea has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The IQWiG examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy for DME.

According to the findings, an added benefit in this therapeutic indication is not proven: The data showed no relevant differences between the treatment groups for patients in whom the fovea centralis is also affected. The drug manufacturer did not submit any data for other patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK